Annual FCF
-$29.48 M
-$9.17 M-45.15%
30 September 2022
Summary:
NeuBase Therapeutics annual free cash flow is currently -$29.48 million, with the most recent change of -$9.17 million (-45.15%) on 30 September 2022. During the last 3 years, it has fallen by -$9.17 million (-45.15%).NBSE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$2.00 M
+$1.64 M+45.04%
30 September 2023
Summary:
NeuBase Therapeutics quarterly free cash flow is currently -$2.00 million, with the most recent change of +$1.64 million (+45.04%) on 30 September 2023.NBSE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$14.85 M
+$4.66 M+23.91%
30 September 2023
Summary:
NeuBase Therapeutics TTM free cash flow is currently -$14.85 million, with the most recent change of +$4.66 million (+23.91%) on 30 September 2023.NBSE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -45.1% | +65.4% | +26.9% |
| 5 y5 years | -767.6% | -74.8% | -336.9% |
NBSE Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | <-9999.0% | -786.1% | -4893.5% |
NeuBase Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$2.00 M(-45.0%) | -$14.85 M(-23.9%) |
| June 2023 | - | -$3.64 M(+5.3%) | -$19.51 M(-21.8%) |
| Mar 2023 | - | -$3.46 M(-39.7%) | -$24.95 M(-16.4%) |
| Dec 2022 | - | -$5.74 M(-13.9%) | -$29.83 M(+1.2%) |
| Sept 2022 | -$29.48 M(+45.2%) | -$6.67 M(-26.6%) | -$29.48 M(+3.1%) |
| June 2022 | - | -$9.08 M(+8.9%) | -$28.60 M(+8.6%) |
| Mar 2022 | - | -$8.34 M(+54.7%) | -$26.34 M(+21.2%) |
| Dec 2021 | - | -$5.39 M(-6.8%) | -$21.73 M(+7.0%) |
| Sept 2021 | -$20.31 M(+77.8%) | -$5.78 M(-15.2%) | -$20.31 M(+10.1%) |
| June 2021 | - | -$6.82 M(+82.9%) | -$18.45 M(+25.4%) |
| Mar 2021 | - | -$3.73 M(-6.1%) | -$14.71 M(+14.1%) |
| Dec 2020 | - | -$3.97 M(+1.3%) | -$12.89 M(+12.8%) |
| Sept 2020 | -$11.43 M(+236.3%) | -$3.92 M(+27.1%) | -$11.43 M(+32.1%) |
| June 2020 | - | -$3.09 M(+61.6%) | -$8.65 M(+38.0%) |
| Mar 2020 | - | -$1.91 M(-23.9%) | -$6.27 M(+17.4%) |
| Dec 2019 | - | -$2.51 M(+119.1%) | -$5.34 M(+57.2%) |
| Sept 2019 | -$3.40 M(-64.2%) | -$1.15 M(+62.6%) | -$3.40 M(+19.3%) |
| June 2019 | - | -$704.60 K(-28.2%) | -$2.85 M(-14.3%) |
| Mar 2019 | - | -$981.20 K(+73.1%) | -$3.33 M(-43.3%) |
| Dec 2018 | - | -$566.80 K(-5.0%) | -$5.86 M(-38.2%) |
| Sept 2018 | -$9.49 M(-50.8%) | -$596.60 K(-49.5%) | -$9.49 M(-33.0%) |
| June 2018 | - | -$1.18 M(-66.4%) | -$14.17 M(-17.2%) |
| Mar 2018 | - | -$3.52 M(-16.1%) | -$17.11 M(-2.6%) |
| Dec 2017 | - | -$4.20 M(-20.5%) | -$17.56 M(-9.0%) |
| Sept 2017 | -$19.30 M(+20.6%) | -$5.27 M(+28.1%) | -$19.30 M(+1.3%) |
| June 2017 | - | -$4.12 M(+3.8%) | -$19.05 M(-0.4%) |
| Mar 2017 | - | -$3.97 M(-33.1%) | -$19.12 M(+2.8%) |
| Dec 2016 | - | -$5.94 M(+17.9%) | -$18.60 M(+16.2%) |
| Sept 2016 | -$16.00 M(+47.1%) | -$5.03 M(+20.3%) | -$16.00 M(+21.4%) |
| June 2016 | - | -$4.19 M(+21.5%) | -$13.18 M(+22.4%) |
| Mar 2016 | - | -$3.44 M(+3.2%) | -$10.77 M(-6.2%) |
| Dec 2015 | - | -$3.34 M(+50.9%) | -$11.48 M(+5.5%) |
| Sept 2015 | -$10.88 M(+102.9%) | -$2.21 M(+24.7%) | -$10.88 M(+6.2%) |
| June 2015 | - | -$1.77 M(-57.3%) | -$10.24 M(-1.7%) |
| Mar 2015 | - | -$4.15 M(+51.7%) | -$10.42 M(+53.1%) |
| Dec 2014 | - | -$2.74 M(+73.6%) | -$6.81 M(+27.0%) |
| Sept 2014 | -$5.36 M | -$1.58 M(-19.0%) | -$5.36 M(+13.9%) |
| June 2014 | - | -$1.95 M(+258.6%) | -$4.71 M(+35.0%) |
| Mar 2014 | - | -$542.90 K(-58.0%) | -$3.49 M(+5.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | - | -$1.29 M(+39.8%) | -$3.32 M(+23.5%) |
| Sept 2013 | -$2.69 M(+50.5%) | -$924.40 K(+27.0%) | -$2.69 M(+17.7%) |
| June 2013 | - | -$727.90 K(+93.5%) | -$2.29 M(+15.3%) |
| Mar 2013 | - | -$376.20 K(-43.1%) | -$1.98 M(-9.5%) |
| Dec 2012 | - | -$661.10 K(+27.2%) | -$2.19 M(+22.6%) |
| Sept 2012 | -$1.79 M(+77.9%) | -$519.80 K(+22.4%) | -$1.79 M(+6.6%) |
| June 2012 | - | -$424.70 K(-27.4%) | -$1.68 M(+13.2%) |
| Mar 2012 | - | -$585.20 K(+127.2%) | -$1.48 M(+34.8%) |
| Dec 2011 | - | -$257.60 K(-37.0%) | -$1.10 M(+9.4%) |
| Sept 2011 | -$1.00 M(+83.7%) | -$408.80 K(+78.0%) | -$1.00 M(+33.7%) |
| June 2011 | - | -$229.60 K(+13.0%) | -$751.40 K(+19.1%) |
| Mar 2011 | - | -$203.10 K(+24.5%) | -$630.90 K(+15.1%) |
| Dec 2010 | - | -$163.10 K(+4.8%) | -$548.00 K(+5.0%) |
| Sept 2010 | -$546.80 K(-23.5%) | -$155.60 K(+42.6%) | -$521.70 K(-21.9%) |
| June 2010 | - | -$109.10 K(-9.2%) | -$667.80 K(-12.1%) |
| Mar 2010 | - | -$120.20 K(-12.1%) | -$759.80 K(-2.7%) |
| Dec 2009 | - | -$136.80 K(-54.7%) | -$780.80 K(+9.2%) |
| Sept 2009 | -$715.20 K(+37.7%) | -$301.70 K(+50.0%) | -$715.20 K(+65.2%) |
| June 2009 | - | -$201.10 K(+42.4%) | -$433.00 K(-21.0%) |
| Mar 2009 | - | -$141.20 K(+98.3%) | -$547.90 K(+34.7%) |
| Dec 2008 | - | -$71.20 K(+265.1%) | -$406.70 K(-21.7%) |
| Sept 2008 | -$519.50 K(-90.9%) | -$19.50 K(-93.8%) | -$519.50 K(+3.9%) |
| June 2008 | - | -$316.00 K(<-9900.0%) | -$500.00 K(+171.7%) |
| Mar 2008 | - | $0.00(-100.0%) | -$184.00 K(0.0%) |
| Dec 2007 | - | -$184.00 K(+4081.8%) | -$184.00 K(-67.8%) |
| Sept 2007 | -$5.74 M(+904.7%) | - | - |
| Dec 2006 | -$571.10 K(-436.1%) | -$4400.00(+120.0%) | -$571.10 K(+16.5%) |
| Sept 2006 | - | -$2000.00(-99.7%) | -$490.20 K(+149.7%) |
| June 2006 | - | -$677.50 K(-700.6%) | -$196.30 K(-191.3%) |
| Mar 2006 | - | $112.80 K(+47.5%) | $215.00 K(+26.5%) |
| Dec 2005 | $169.90 K(-7.6%) | $76.50 K(-73.8%) | $169.90 K(-624.4%) |
| Sept 2005 | - | $291.90 K(-209.7%) | -$32.40 K(-87.5%) |
| June 2005 | - | -$266.20 K(-493.2%) | -$260.00 K(-310.2%) |
| Mar 2005 | - | $67.70 K(-153.8%) | $123.70 K(-32.7%) |
| Dec 2004 | $183.90 K(-533.7%) | -$125.80 K(-295.6%) | $183.90 K(-40.6%) |
| Sept 2004 | - | $64.30 K(-45.3%) | $309.70 K(+26.2%) |
| June 2004 | - | $117.50 K(-8.1%) | $245.40 K(+91.9%) |
| Mar 2004 | - | $127.90 K | $127.90 K |
| Dec 2003 | -$42.40 K | - | - |
FAQ
- What is NeuBase Therapeutics annual free cash flow?
- What is the all time high annual FCF for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for NeuBase Therapeutics?
- What is NeuBase Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for NeuBase Therapeutics?
What is NeuBase Therapeutics annual free cash flow?
The current annual FCF of NBSE is -$29.48 M
What is the all time high annual FCF for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual free cash flow is $183.90 K
What is NeuBase Therapeutics quarterly free cash flow?
The current quarterly FCF of NBSE is -$2.00 M
What is the all time high quarterly FCF for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly free cash flow is $291.90 K
What is NeuBase Therapeutics TTM free cash flow?
The current TTM FCF of NBSE is -$14.85 M
What is the all time high TTM FCF for NeuBase Therapeutics?
NeuBase Therapeutics all-time high TTM free cash flow is $309.70 K